David O. Watson Sells 4,965 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 4,965 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $142,495.50. Following the sale, the general counsel now owns 107,756 shares of the company’s stock, valued at approximately $3,092,597.20. The trade was a 4.40 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Apellis Pharmaceuticals Stock Up 4.8 %

NASDAQ:APLS opened at $29.03 on Thursday. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The stock has a market cap of $3.61 billion, a price-to-earnings ratio of -14.30 and a beta of 0.94. The stock has a 50-day moving average price of $31.86 and a two-hundred day moving average price of $33.45. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The firm had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s quarterly revenue was up 78.3% on a year-over-year basis. During the same period in the prior year, the company earned ($1.17) earnings per share. As a group, equities analysts expect that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Envestnet Asset Management Inc. boosted its position in shares of Apellis Pharmaceuticals by 42.2% during the second quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock worth $5,161,000 after buying an additional 39,931 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after buying an additional 735,160 shares during the period. Profund Advisors LLC boosted its position in Apellis Pharmaceuticals by 90.7% during the second quarter. Profund Advisors LLC now owns 42,968 shares of the company’s stock valued at $1,648,000 after purchasing an additional 20,435 shares during the last quarter. Algert Global LLC boosted its position in Apellis Pharmaceuticals by 137.8% during the second quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after purchasing an additional 71,650 shares during the last quarter. Finally, Edgestream Partners L.P. boosted its position in Apellis Pharmaceuticals by 240.4% during the second quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock valued at $2,093,000 after purchasing an additional 38,541 shares during the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

APLS has been the subject of a number of recent analyst reports. The Goldman Sachs Group downgraded Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $36.00 price objective for the company. in a report on Tuesday, December 17th. Evercore ISI upgraded Apellis Pharmaceuticals to a “strong-buy” rating in a report on Thursday, October 31st. Bank of America dropped their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Mizuho dropped their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a report on Thursday, October 24th. Finally, Oppenheimer dropped their price objective on Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $46.65.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).